Treatment considerations in pulmonary coccidioidomycosis

Carlos A. Hartmann, Wint T. Aye, Janis E. Blair

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Coccidioidomycosis is an endemic fungal infection caused by the soil-dwelling fungi, Coccidioides species. Coccidioidal infections may be asymptomatic in up to two-thirds of infected persons. Pulmonary coccidioidomycosis is the most common form of symptomatic infection. Fluconazole is the antifungal agent typically used to treat pulmonary coccidioidomycosis. Other azoles and amphotericin B products may be prescribed to treat nuanced aspects of coccidioidomycosis. Areas covered: This review discusses current literature regarding medical treatment options, including the various triazoles and amphotericin B products. In addition, we discuss uncomplicated and complicated pulmonary infections and their sequelae and the approach to managing coccidioidomycosis in certain populations of patients, such as pregnant women, transplant recipients, individuals infected with human immunodeficiency virus, and recipients of tumor necrosis factor-α inhibitors. Expert commentary: Symptomatic coccidioidomycosis can present physicians with a number of challenges, including the lack of sensitivity and specificity of diagnostic tests and lack of a standard treatment approach for all patients with the infection. Ongoing and future clinical trials will determine the optimal diagnostic, therapeutic, and prophylactic approaches, particularly for patients with comorbid conditions.

Original languageEnglish (US)
Pages (from-to)1079-1091
Number of pages13
JournalExpert Review of Respiratory Medicine
Volume10
Issue number10
DOIs
StatePublished - Oct 2 2016

Fingerprint

Coccidioidomycosis
Lung
Amphotericin B
Infection
Therapeutics
Coccidioides
Azoles
Triazoles
Mycoses
Fluconazole
Antifungal Agents
Routine Diagnostic Tests
Pregnant Women
Fungi
Soil
Tumor Necrosis Factor-alpha
Clinical Trials
HIV
Physicians
Sensitivity and Specificity

Keywords

  • Coccidioides
  • coccidioidomycosis
  • drug treatment
  • valley fever

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health

Cite this

Treatment considerations in pulmonary coccidioidomycosis. / Hartmann, Carlos A.; Aye, Wint T.; Blair, Janis E.

In: Expert Review of Respiratory Medicine, Vol. 10, No. 10, 02.10.2016, p. 1079-1091.

Research output: Contribution to journalReview article

Hartmann, Carlos A. ; Aye, Wint T. ; Blair, Janis E. / Treatment considerations in pulmonary coccidioidomycosis. In: Expert Review of Respiratory Medicine. 2016 ; Vol. 10, No. 10. pp. 1079-1091.
@article{aa1c2af0cd274ecc9130c56a9b8e465f,
title = "Treatment considerations in pulmonary coccidioidomycosis",
abstract = "Introduction: Coccidioidomycosis is an endemic fungal infection caused by the soil-dwelling fungi, Coccidioides species. Coccidioidal infections may be asymptomatic in up to two-thirds of infected persons. Pulmonary coccidioidomycosis is the most common form of symptomatic infection. Fluconazole is the antifungal agent typically used to treat pulmonary coccidioidomycosis. Other azoles and amphotericin B products may be prescribed to treat nuanced aspects of coccidioidomycosis. Areas covered: This review discusses current literature regarding medical treatment options, including the various triazoles and amphotericin B products. In addition, we discuss uncomplicated and complicated pulmonary infections and their sequelae and the approach to managing coccidioidomycosis in certain populations of patients, such as pregnant women, transplant recipients, individuals infected with human immunodeficiency virus, and recipients of tumor necrosis factor-α inhibitors. Expert commentary: Symptomatic coccidioidomycosis can present physicians with a number of challenges, including the lack of sensitivity and specificity of diagnostic tests and lack of a standard treatment approach for all patients with the infection. Ongoing and future clinical trials will determine the optimal diagnostic, therapeutic, and prophylactic approaches, particularly for patients with comorbid conditions.",
keywords = "Coccidioides, coccidioidomycosis, drug treatment, valley fever",
author = "Hartmann, {Carlos A.} and Aye, {Wint T.} and Blair, {Janis E.}",
year = "2016",
month = "10",
day = "2",
doi = "10.1080/17476348.2017.1234378",
language = "English (US)",
volume = "10",
pages = "1079--1091",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Treatment considerations in pulmonary coccidioidomycosis

AU - Hartmann, Carlos A.

AU - Aye, Wint T.

AU - Blair, Janis E.

PY - 2016/10/2

Y1 - 2016/10/2

N2 - Introduction: Coccidioidomycosis is an endemic fungal infection caused by the soil-dwelling fungi, Coccidioides species. Coccidioidal infections may be asymptomatic in up to two-thirds of infected persons. Pulmonary coccidioidomycosis is the most common form of symptomatic infection. Fluconazole is the antifungal agent typically used to treat pulmonary coccidioidomycosis. Other azoles and amphotericin B products may be prescribed to treat nuanced aspects of coccidioidomycosis. Areas covered: This review discusses current literature regarding medical treatment options, including the various triazoles and amphotericin B products. In addition, we discuss uncomplicated and complicated pulmonary infections and their sequelae and the approach to managing coccidioidomycosis in certain populations of patients, such as pregnant women, transplant recipients, individuals infected with human immunodeficiency virus, and recipients of tumor necrosis factor-α inhibitors. Expert commentary: Symptomatic coccidioidomycosis can present physicians with a number of challenges, including the lack of sensitivity and specificity of diagnostic tests and lack of a standard treatment approach for all patients with the infection. Ongoing and future clinical trials will determine the optimal diagnostic, therapeutic, and prophylactic approaches, particularly for patients with comorbid conditions.

AB - Introduction: Coccidioidomycosis is an endemic fungal infection caused by the soil-dwelling fungi, Coccidioides species. Coccidioidal infections may be asymptomatic in up to two-thirds of infected persons. Pulmonary coccidioidomycosis is the most common form of symptomatic infection. Fluconazole is the antifungal agent typically used to treat pulmonary coccidioidomycosis. Other azoles and amphotericin B products may be prescribed to treat nuanced aspects of coccidioidomycosis. Areas covered: This review discusses current literature regarding medical treatment options, including the various triazoles and amphotericin B products. In addition, we discuss uncomplicated and complicated pulmonary infections and their sequelae and the approach to managing coccidioidomycosis in certain populations of patients, such as pregnant women, transplant recipients, individuals infected with human immunodeficiency virus, and recipients of tumor necrosis factor-α inhibitors. Expert commentary: Symptomatic coccidioidomycosis can present physicians with a number of challenges, including the lack of sensitivity and specificity of diagnostic tests and lack of a standard treatment approach for all patients with the infection. Ongoing and future clinical trials will determine the optimal diagnostic, therapeutic, and prophylactic approaches, particularly for patients with comorbid conditions.

KW - Coccidioides

KW - coccidioidomycosis

KW - drug treatment

KW - valley fever

UR - http://www.scopus.com/inward/record.url?scp=84988674503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988674503&partnerID=8YFLogxK

U2 - 10.1080/17476348.2017.1234378

DO - 10.1080/17476348.2017.1234378

M3 - Review article

C2 - 27635942

AN - SCOPUS:84988674503

VL - 10

SP - 1079

EP - 1091

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 10

ER -